Teva Price Earnings Ratio from 2010 to 2024

TEVA Stock  USD 22.21  0.12  0.54%   
Teva Pharma's Price Earnings Ratio is decreasing over the years with slightly volatile fluctuation. Overall, Price Earnings Ratio is projected to go to -20.1 this year. From 2010 to 2024 Teva Pharma Price Earnings Ratio quarterly data regression line had arithmetic mean of  78.47 and significance of  0.07. View All Fundamentals
 
Price Earnings Ratio  
First Reported
2010-12-31
Previous Quarter
(21.16)
Current Value
(20.10)
Quarterly Volatility
259.0246586
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Teva Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Teva Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 B, Interest Expense of 1.1 B or Total Revenue of 9.5 B, as well as many indicators such as Price To Sales Ratio of 0.71, Dividend Yield of 0.0041 or PTB Ratio of 1.5. Teva financial statements analysis is a perfect complement when working with Teva Pharma Valuation or Volatility modules.
  
Check out the analysis of Teva Pharma Correlation against competitors.

Latest Teva Pharma's Price Earnings Ratio Growth Pattern

Below is the plot of the Price Earnings Ratio of Teva Pharma Industries over the last few years. It is Teva Pharma's Price Earnings Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Teva Pharma's overall financial position and show how it may be relating to other accounts over time.
Price Earnings Ratio10 Years Trend
Slightly volatile
   Price Earnings Ratio   
       Timeline  

Teva Price Earnings Ratio Regression Statistics

Arithmetic Mean78.47
Coefficient Of Variation330.08
Mean Deviation127.59
Median13.61
Standard Deviation259.02
Sample Variance67,094
Range1K
R-Value(0.48)
Mean Square Error55,602
R-Squared0.23
Significance0.07
Slope(27.81)
Total Sum of Squares939,313

Teva Price Earnings Ratio History

2024 -20.1
2023 -21.16
2022 -4.26
2021 22.92
2020 -2.61
2019 -10.8
2018 -7.44

About Teva Pharma Financial Statements

Teva Pharma stakeholders use historical fundamental indicators, such as Teva Pharma's Price Earnings Ratio, to determine how well the company is positioned to perform in the future. Although Teva Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Teva Pharma's assets and liabilities are reflected in the revenues and expenses on Teva Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Teva Pharma Industries. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Earnings Ratio(21.16)(20.10)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.4
Earnings Share
(0.85)
Revenue Per Share
14.879
Quarterly Revenue Growth
0.125
Return On Assets
0.0556
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.